重组胰高血糖素样肽-1与人血清白蛋白融合蛋白的纯化及活性研究

利用构建的重组菌株Pichia pastoris GS115/GLP-1/HSA,在10L发酵罐中表达了胰高血糖素样肽-1与人血清白蛋白融合蛋白(GLP-1/HSA),表达量为63.6mg/L。发酵液经中空纤维柱浓缩、疏水层析、阴离子交换层析和凝胶过滤分离纯化,获得了较高纯度的GLP-1/HSA,经HPLC分析纯度达95.8%。进一步的体内活性分析结果表明,GLP-1/HSA不仅具有天然GLP-1的生物活性,而且在给药后4h仍能发挥显著性降血糖作用。以上结果表明,利用Pichia pastoris分泌型表达系统和建立的分离纯化方法,能获得大量较高纯度的GLP-1/HSA,为进一步研究和开发能够用于糖尿病临床治疗的长效GLP-1类似物奠定了基础。     

西瓜花叶病毒HC-Pro基因在毕赤酵母中的分泌表达与功能研究

利用RT-PCR方法扩增出西瓜花叶病毒HC-Pro的基因,长度为1371bp,并构建了真核表达质粒pPIC9K-WHC。将重组质粒经SalⅠ单酶切后电转化Pichia pastoris GS115菌株,经PCR鉴定与G418、MD和MM培养基筛选,获得Mut⁺/His⁺表型高拷贝转化子。经1%甲醇诱导5d后,SDS-PAGE检测发酵液上清,在66kD处有一特异蛋白条带表达。Western blot 鉴定表明,表达蛋白可以和HC-Pro蛋白抗血清发生结合反应。Far-Western blot 证明该蛋白能与西瓜花叶病毒CP蛋白结合,支持了HC-Pro蛋白协助传毒的“桥梁”学说。     

西瓜花叶病毒HC-Pro基因在毕赤酵母中的分泌表达与功能研究

利用RT-PCR方法扩增出西瓜花叶病毒HC-Pro的基因,长度为1371bp,并构建了真核表达质粒pPIC9K-WHC。将重组质粒经SalⅠ单酶切后电转化Pichia pastoris GS115菌株,经PCR鉴定与G418、MD和MM培养基筛选,获得Mut⁺/His⁺表型高拷贝转化子。经1%甲醇诱导5d后,SDS-PAGE检测发酵液上清,在66kD处有一特异蛋白条带表达。Western blot 鉴定表明,表达蛋白可以和HC-Pro蛋白抗血清发生结合反应。Far-Western blot 证明该蛋白能与西瓜花叶病毒CP蛋白结合,支持了HC-Pro蛋白协助传毒的“桥梁”学说。     

重组人血清白蛋白在Pichia pastoris中分泌表达影响因素的研究

为获得高产稳产重组人血清白蛋白的Pichia pastoris细胞株用于高密度发酵,构建了多种分泌表达载体,在Pichia pastoris中作表达,研究表达载体构建等因素对表达量的影响。发现采用酿酒酵母α性成熟因子前导肽比人血清白蛋白天然前导肽作为分泌信号肽的表达量要高10%左右。而载体整合方式、整合拷贝数、5’非翻译区的改造和甲醇利用表型等对表达量无规律性影响。筛选到的高表达株经高密度发酵,细胞湿重达460 g/L,发酵液上清的人血清白蛋白含量为1.0 g/L。     

人源性抗HBsAg抗体Fab段在酵母中的表达

通过分步整合的方式,将人源性抗乙肝表面抗原（HBsAg）抗体Fab的轻、重链基因分步整合到巴斯德毕赤（Pichia pastoris）酵母GS115菌株的染色体上,经甲醇诱导,成功地分泌表达出抗HBsAg抗体的Fab片段,表达量达50～80mg/L。ELISA结果显示重组酵母分泌表达出的Fab具有较强的结合HBsAg的能力。通过抗Fab的抗体柱亲和层析,纯化出了纯度较高的Fab产品。     

人血管内皮生长因子功能域受体的筛选及其生物学活性研究

利用PCR技术,从人胎盘cDNA文库扩增出4个截短的人血管内皮生长因子受体(Flt-1)cDNA,分别含胞外第2,1-2,2-3,1-3个loop,应用酵母双杂交系统对Flt-1的最小配体结合域进行了研究,结果表明,不仅其胞外1-3loop能与hVEGF₁₆₅结合,比其更小的片段2-3loop也具有与配体结合的能力.进一步构建了重组表达质粒pPIC9K/Flt-1(1-3)和pPIC9K/Flt-1(2-3),转化Pichia pastoris酵母菌GS115,摇瓶培养,经1%甲醇诱导,表达的Flt-1以可溶性分子形式存在于上清中,诱导4 d的表达量占上清总蛋白质的60%以上.表达产物经CM-Sepharose FF阳离子交换层析和Sephacryl S-100分子筛层析纯化,纯度达90%以上.体外生物学活性检测表明,表达的可溶性Flt-1(2-3)具有与Flt-1(1-3)接近的结合hVEGF₁₆₅的能力和抑制hVEGF₁₆₅对HUVEC的促增殖功能.进一步的动物模型实验证实,可溶性Flt-1(2-3)具有显著的抑制hVEGF₁₆₅促进新生血管形成的功能.     

里氏木霉内切葡萄糖苷酶Ⅳ在毕赤酵母中的表达*

进行了内切葡萄糖苷酶Ⅳ(EGⅣ)在毕赤酵母(Pichia pastoris)表达系统中的表达。采用RT-PCR的方法从里氏木霉(Trichoderma reesei)中分离到eg4基因。将eg4基因与毕赤酵母表达载体pPICZαA连接,得到重组质粒pPICZαA-eg4。将该重组质粒线性化后转化毕赤酵母GS115,eg4基因通过同源重组被整合到毕赤酵母的染色体上,并处于酵母α因子的下游,得到重组菌株P.pastoris-EGⅣ1。在甲醇     

甲醇酵母Pichia pastoris高水平表达有活性的辣根过氧化物酶

表达有活性的辣根过氧化物酶(HRP)不仅可以深入揭示HRP结构与功能及其生理作用规律,而且为HRP的广泛需要提供新的来源.为了在甲醇酵母P.pastoris中成功表达,将编码HRP-C成熟肽的cDNA构建到pPIC9上,再转化到P.pastoris中,筛选到了分泌表达非糖基化HRP和高糖基化HRP(分子质量超过100 ku)两种主要产物的重组细胞株.优化表达条件,目标产物在摇瓶发酵液中高效表达,可达4～6 g/L.并且直接从发酵液中可获得具有活性的高糖基化HRP,每毫升发酵液中酶活力约有2 U,经初步的纯化HRP具有最大吸收峰403 nm.     

重组刺桐胰蛋白酶抑制剂a的制备及其在tPA突变体纯化中的应用

将基因工程菌株E.coliBL21(DE3) pET22b-mETIa高密度发酵,用异丙基硫代-β-D-半乳糖苷(IPTG)诱导,重组刺桐胰蛋白酶抑制剂a(rETIa)蛋白在E.coli中得到较高水平表达,表达量占菌体总蛋白的40%以上.经菌体破碎、包涵体变性、复性,二步柱层析纯化得到电泳纯的rETIa蛋白.测得rETIa对t-PA突变体(NTA)的抑制平衡常数K_i为8.72×10^－8 mol/L.据此利用纯化的rETIa蛋白制备rETIa-Sepharose 4B亲和层析柱.直接一步纯化NTA复性液,纯化的NTA纯度达90 %以上,收率为96.2 %,纯化倍数为13.2,比活为(565.7±71.3) U/μg.     

植物防御素PD5基因在毕赤酵母中的分泌表达*

将植物防御素PD5基因克隆到载体pPIC9的XholI和EcoRI位点之间,得到重组载体pPIC9/PD5。pPIC9/PDF5经BglII线性化,电转化法转入Pichia pastorisGS115,MD和MM平板筛选表型为His⁺Mut^s的转化子,PCR鉴定阳性转化子。转化子D24用BMGY培养至OD₆₀₀为6.0时,经BMM诱导,上清液用Tricien-SDS-PA     

One-step purification of a fusion protein of glucagon-like peptide-1 and human serum albumin expressed in pichia pastoris by an immunomagnetic separation technique

Glucagon-like peptide-1 (GLP-1) has great therapeutic potential to treat diabetes type 2, mainly due to its unique glucose-dependent stimulation of insulin secretion profiles, but its clinical application is limited by its short half-life in vivo, which resultes from degradation by dipeptidyl peptidase IV and/or renal clearance. Developing long-acting GLP-1 analogs is therefore an important step toward using them therapeutically. In this study, the GLP-1/human serum albumin (HSA) fusion protein gene was cloned into the secretor type expression vector pPIC9K and subsequently expressed in Pichia pastoris. The expression quantity reached 58.5 mg/l in small-scale incubation. After optimization and characterization, the GLP-1/HSA fusion protein was successfully purified from the supernatant of the broth using immunomagnetic cellulose microspheres. HPLC showed that the purified GLP-1/HSA had an overall purity of 93.9%, and matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF-MS) confirmed the fusion protein exhibited the expected molecular mass of 70 kDa. Furthermore, that analysis of in vivo activity indicated that GLP-1/HSA reduced the blood glucose level after intraperitoneal administration to Chinese Kunming mice in a dose-dependent manner, and the effects held significantly 4 h after administration. Overall, this study illustrates the development of a long-acting GLP-1/HSA fusion protein expressed in Pichia pastoris.     

重组人血清白蛋白在Pichia pastoris中的表达与纯化

为实现重组人血清白蛋白（ｒＨＳＡ）的开发,对构建的酵母工程菌Ｐｉｃｈｉａ ｐａｓｔｏｒｉｓ ＧＳ１１５／ＨＳＡ进行了表达条件的优化,摇瓶中将表达ｒＨＳＡ的量提高到１５０ｍｇ／Ｌ。经中空纤维柱浓缩、Ｐｈｅｎｙｌ－Ｓｅｐｈａｒｏｓｅ分离和抗ＨＳＡ－Ｓｅｐｈａｒｏｓｅ亲和层析纯化获得电泳纯的重组人血清白蛋白。     

Expression and purification of active recombinant human bikunin in Pichia pastoris

Bikunin is a proteoglycan exhibiting broad-spectrum inhibitory activity against serine proteases and could potentially suppress tumor cell invasion and metastasis. Here, we have successfully expressed recombinant human bikunin (rh-bikunin) in the methylotrophic yeast Pichia pastoris and established the purification procedure. The cDNA encoding human bikunin was cloned by PCR and inserted into the expression vector pPICZαC. After expressed in shake flask, rh-bikunin was produced in an 80-L fermenter and purified by cation exchange chromatography and reverse phase chromatography. The rh-bikunin was active by trypsin inhibition test. The final expression levels were 55 mg/L and we got totally 1.44 g (5600 inhibitor units/mg) of purified rh-bikunin (purity is 95%) from 40 L of fermentation broth. The rh-bikunin consists of two forms with molecular masses of 24 and 21 kDa, respectively. Both forms were immunoreactive by Western blotting and N-terminals were correctly processed by amino-terminal sequencing. This study provided a new method for expression and purification of active rh-bikunin.     

Expression, purification, and characterization of recombinant human serum albumin fusion protein with two human glucagon-like peptide-1 mutants in Pichia pastoris

Glucagon-like peptide-1 (GLP-1) is a 30-residue peptide hormone secreted by intestinal L-cells in response to nutrient ingestion. In the present study, overlapping PCR technology was employed to construct two GLP-1 mutants (GLP-1(A2G))2 and human albumin (HSA) genes in vitro without linker. The spliced gene, (GLP-1(A2G))2-HSA, was over expressed under the control of promoter AOX1 and Mat alpha signal peptide in Pichia pastoris. SDS-PAGE and Western blotting were applied to assay the recombinant fusion protein in the culture broth. The results demonstrated that the recombinant (GLP-1(A2G))2-HSA concentration in the broth could reach a level of 245.0 mg/L and the expressed fusion protein was capable of cross-reacting with anti-human GLP-1 and anti-human albumin antibody. The recombinant (GLP-1(A2G))2-HSA protein was purified by ultrafiltration, columns of Q-sepharose fast flow and Superdex 75 size-exclusion. The recombinant (GLP-1(A2G))2-HSA protein obtained could lower in vivo glucose concentration in blood and stimulate in vitro islet cell proliferation. In mouse model, the fusion protein was detectable in plasma even 308 h after a single subcutaneous dose of 1.25 mg/kg. The result showed that the terminal biological half-time of the protein was about 54.2 h which is 650-fold longer than that of GLP-1. The pharmacokinetic analysis of the protein suggests its promising application in clinical medicine.     

巴曲酶在毕赤酵母中的高效表达

目的研究巴曲酶在毕赤酵母菌中的表达。方法按Pichiapastoris偏好密码子人工合成巴曲酶全基因,克隆到酵母分泌型表达载体pPICZaA中,将重组载体酶切线性化后经电转化转入X-33。筛选鉴定转化子．经摇瓶发酵甲醇诱导,酵母菌分泌表达有凝血活性的巴曲酶。经SDS-PAGE电泳确定其分子量为33．0 kDa．免疫印迹证明重组巴曲酶具有天然巴曲酶的免疫活性。结果经发酵条件的优化．发酵罐的表达量达到25000Ku／L发酵液。从每升发酵液中可纯化出11．0mg重组巴曲酶。结论巴曲酶毕氏酵母菌成功的构建．为重组巴曲酶止血药的开发奠定了基础。     

人源性抗HBsAg Fab抗体的发酵生产研究

为了适应工业生产的需要,利用fed—batch方法,重组人源性抗HBsAg Fab抗体酵母工程菌在30L发酵罐中进行了高密度发酵,发酵最适温度30℃,pH值范围5．0～5．3,溶氧范围20％～30％。发酵液OD600值达到300时开始诱导,甲醇最佳诱导浓度为10mL／L。重组人源性抗HBsAg Fab抗体经离子交换层析纯化,纯化产品经SDS-PAGE、Western blot进行分析和ELISA方法进行活性测定。结果显示,重组Fab抗体在Fed-batch发酵系统中可高效表达,经过192h的发酵生产,重组人源性抗HBsAg Fab抗体的表达量可达412mg／L。发酵上清经过离子交换层析纯化,获得纯度为95％的重组Fab抗体,该Fab抗体经ELISA分析具有较高的HBsAg抗原亲和力和特异性。结果证实可以通过高密度发酵毕赤酵母工程菌来高效生产重组人源性抗HBsAg Fab抗体,为后续的工业化生产应用奠定了基础。     

纤溶酶抑制剂textilinin-1在毕氏酵母的表达及应用

目的研究真核表达的textilinin-1蛋白纯化品对纤溶酶抑制作用。方法根据textilinin-1的天然氨基酸序列,按照毕氏酵母偏好密码子进行优化,合成textilinin-1基因,重组到pPICZα载体上,并转化至Pichia p.X-33菌种中,实现高效分泌表达,并进行重组textilinin-1活力单位的定义及小鼠断尾试验。结果通过高密度发酵及两步柱层析纯化,最终从10L发酵液中得到6g纯度达97.0%以上的重组textilinin-1。活性研究表明,重组textilinin-1对纤溶酶的活性具有抑制作用,并对tPA所致的小鼠出血倾向有一定的抑制作用。结论重组textilinin-1可抑制纤溶酶活性,并对纤溶性出血小鼠模型有止血作用,具有开发为止血药的潜力。     

Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia pastoris.

A novel recombinant exendin-4 human serum albumin fusion protein (rEx-4/HSA) expressed in Pichia pastoris was prepared and characterized. Ex-4 is a 39-amino acid peptide isolated from the salivary gland of the lizard Heloderma suspectum and is thought to be a novel therapeutic agent for type 2 diabetes. But to gain a continued effect, the peptide has to be injected twice a day owing to its short plasma half-life (t(1/2) = 2.4 h). To extend the half-life of Ex-4 molecule in vivo, we designed a genetically engineered Ex-4/HSA fusion protein. Between Ex-4 and HSA, a peptide linker GGGGS was inserted and the fusion protein was expressed in methylotrophic yeast P. pastoris with native HSA secretion signal sequence. The recombinant protein was secreted correctly and was obtained with high purity (typically > 98%) by a three-step purification procedure. cAMP assay demonstrated that the fusion protein had a bioactivity similar to Ex-4 for interaction with GLP-1 receptors in vitro. Results from oral glucose tolerance test indicated that rEx-4/HSA could effectively improve glucose tolerance in diabetic db/db mice. Pharmacokinetics studies in cynomologus monkeys also showed that rEx-4/HSA had a much longer plasma half-life. Therefore, rEx-4/HSA fusion protein could potentially be used as a new recombinant biodrug for type 2 diabetes therapy.     

Routine manufacture of recombinant proteins using expanded bed adsorption chromatography

Two different recombinant human proteins were purified directly from Pichia pastoris whole cell fermentation broth, containing 30–44% biomass (wet weight percent), by strong cation exchange expanded bed adsorption chromatography. Expanded bed adsorption chromatography provided clarification, product purification and product concentration in a single unit operation at large scale (2000-l nominal fermentation volume). The efficiency of expanded bed adsorption chromatography resulted in a short process time, high process yield, and limited proteolytic degradation of the target proteins. The separations were operated using a 60-cm (d) column run at 14 l/min. For one protein, expanded bed adsorption chromatography resulted in an average product recovery of 113% (relative to fermentation supernatant) and a purity of 89% (n=10). For the other protein, the average product recovery was 99% (relative to fermentation supernatant) and the purity was 62.1 (n=10). Laboratory experiments showed that biomass reduced product dynamic binding capacity for protein 2.